本报告导读：继续推荐创新药械及产业链。投资要点：继续推荐创新 药械及产业链。维持以下A 股标的增持评级：恒瑞医药、科伦药业、华东医药、恩华药业、特宝生物、京新药业、益方生物、药明康德、泰格医药、乐普医疗、联影医疗、微电生理，并将上述标的纳入国泰海通医药2026 年1 月月度组合。维持以下H股标的增持评级：翰森制药、三生制药、科伦博泰生物、康方生物、映恩生物，百济神州、相关标的：信达生物、药明康德。...
Source Link本报告导读：继续推荐创新药械及产业链。投资要点：继续推荐创新 药械及产业链。维持以下A 股标的增持评级：恒瑞医药、科伦药业、华东医药、恩华药业、特宝生物、京新药业、益方生物、药明康德、泰格医药、乐普医疗、联影医疗、微电生理，并将上述标的纳入国泰海通医药2026 年1 月月度组合。维持以下H股标的增持评级：翰森制药、三生制药、科伦博泰生物、康方生物、映恩生物，百济神州、相关标的：信达生物、药明康德。...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.